Marco gives thoracic oncologists and pulmonologists instant access to updated lung cancer evidence, including molecular classification across EGFR/ALK/ROS1/KRAS, immunotherapy guidance by PD-L1 expression and phase III trial data. The AI agent processes and synthesizes information from thousands of sources to support complex therapeutic decisions.
Some answers to questions we often receive
Yes. Marco integrates updated evidence on EGFR (exons 19/21 and rare mutations), ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14 skipping, RET and HER2, including available targeted therapies and efficacy data from pivotal trials for each alteration.
Marco includes NCCN, ESMO, IASLC and ASCO guidelines for non-small cell and small cell lung cancer, continuously updated. It also integrates FDA and EMA approvals and recommendations from major oncology societies on recent drug approvals.
Marco synthesizes known resistance mechanisms for each TKI (T790M for EGFR, kinase domain mutations for ALK) and post-progression therapeutic options per current guidelines, including the role of osimertinib, lorlatinib and available clinical trials.
Marco synthesizes evidence on PD-L1 thresholds (≥1%, ≥50%) and their implications for pembrolizumab monotherapy or combination use, integrating KEYNOTE-024, KEYNOTE-189 and other key studies by histology and disease stage.
Yes. Marco integrates evidence on ctDNA liquid biopsy for driver mutation detection when tissue biopsy is insufficient, including current ESMO and NCCN recommendations on its role in first-line testing and acquired resistance detection.
Absolutely. Marco covers the full spectrum: curative-intent surgery, adjuvant indications with osimertinib or chemotherapy, surveillance criteria and recurrence management, with updated evidence from trials such as ADAURA and PEARLS/KEYNOTE-091.
Keeping pace with EGFR, ALK, KRAS and immunotherapy trial data in lung cancer is impossible without a dedicated evidence tool.